Social Media in the Pharmaceutical Industry Conference 2019

SMi Group21 - 23 January 2019, London, UK.
SMi Group are delighted to present the return of their 11th annual Social Media in the Pharmaceutical Industry conference to London on the 21st - 23rd January 2019. Social media is the perfect channel for pharmaceutical companies to educate, market, listen and connect with customers, patients and physicians. How the pharmaceutical industry utilize social media is particularly complex as regulators such as the FDA have not yet written the rules about how pharmaceuticals can engage with potential customers and patients.

Join SMi's 11th annual Social Media in the Pharmaceutical Industry conference to learn the best way your company can benefit from a robust social media strategy. Hear from industry experts on how to leverage social media platforms by keeping the patient at the forefront and exploring the latest advances in digital application such as Artificial Intelligence, challenges and techniques in the field of 'social pharma'.

How Will You Benefit?

Network and learn from leading professionals such as:

  • [Chair] Jason Browning, Global Head of Digital Communications & Social Media, Novartis
  • [Chair] Emma Sutcliffe, Director Patient Engagement and Innovation, NexGen Healthcare Communications
  • Roeland Van der Heiden, Digital Director, AstraZeneca
  • Lin Lei, Associate Director Digital Customer Engagement, Teva
  • Joao Bocas, CEO, DigitalSalutem
  • Paul Tunnah, CEO, PharmaPhorumMedia
  • Jacob D Flindt, Founder, InforMed.pro
  • Alan Shaw, Director, Strategic Planet; Senior Lecturer: Digital Marketing, Northumbria University
  • Dennis Fink, Campaign Manager and Social Media Channel Expert, Qiagen
  • Stefania Alvino, Multichannel Manager, Daiichi Sankyo Co., Ltd.

2019 Featured Highlights

  • Explore a result driven, value focused social media strategy in the pharmaceutical industry
  • Gain insight into procedures and practices required prior to the implementation of social listening
  • Discuss how to personalise the content relationships with AI
  • Understand the optimisation of disease awareness through social media channels
  • Learn how to use social networks and digital communication to engage HCPs
  • GDPR regulations and limitations to product advertisement (with case studies)
  • Pharmacovigilance in social media - specifically in adverse events reporting

For further information and to register, please visit:
http://www.social-media-pharma.com/wpn

Early-Bird Rates

  • Register by 29th September and save £400
  • Register by 31st October and save £200
  • Register by 30th November and save £100

About SMi Group
The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...

Scientists identify common vulnerabilities across …

In a study published online in Science, an international team of almost 200 researchers from 14 leading institutions in six countries, including France with the Institut ...

Sanofi and Translate Bio mRNA COVID-19 vaccine can…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...